Suvodirsen

N/A

Report date: 2024/03/07 13:13:11
NME

Base Information

Drug NameSuvodirsen
Drug Alias NameSuvodirsen sodiumWV-3473WLS-4176BMTR-0139WVE-210201
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionDystroglycan modulators
TargetsDystroglycan
Therapy Area/IndicationsMuscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[9] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesWave Life Sciences Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWave Life Sciences Ltd
Active IndicationsN/A
Inactive IndicationsMuscular Dystrophy, Duchenne

Other Information

ATC CodeN/A
Related LinksN/A